CHICAGO--(BUSINESS WIRE)--NantWorks, LLC today announced that its affiliate company, NantOmics, LLC, the leader in molecular analysis and a member of the NantWorks ecosystem of companies, will present findings on a genome-based investigation in the neoadjuvant GeparSepto trial for breast cancer treatment during the breast cancer session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting, an event bringing together 30,000 oncology professionals from June 1-5, 2018 at McCormick Place in Chicago, Illinois. NantWorks will be exhibiting at booth #7147 during the event. In this seminal study, genomic sequence analysis linked response to neoadjuvant therapy including Abraxane in triple negative breast cancer to a unique molecular signature: defective homologous recombination DNA repair. This signature is often, but not always driven by mutations in the BRCA genes.
“We are excited to present results that might be used to identify tumors with an increased response rate to neoadjuvant chemotherapy,” said Patrick Soon-Shiong, MD, founder of NantWorks. “The clinical relevance of mutational signatures has not been studied to a great extent. As such, we’re looking forward to continuing this area of study to determine the clinical behavior of breast cancer.”
Presentation Details
Signatures
of mutational processes and response to neoadjuvant chemotherapy in
breast cancer – a genome-based investigation in the neoadjuvant
GeparSepto trial, Abstract #574
WHO: NantOmics,
LLC
WHAT: Breast Cancer—Local/Regional/Adjuvant Session
WHEN: June
2, 8:00-11:30 AM CST
WHERE: Hall A, McCormick Place
Presentation Summary
This study
investigated the individual patterns of mutational signatures that
determine the clinical behavior of breast cancer (BC), in particular
response to neoadjuvant chemotherapy. In the GeparSepto study, women
with primary invasive BC were randomized to either nab-paclitaxel or
solvent-based paclitaxel followed by EC. Pretherapeutic FFPE core
biopsies of HER2-neg BC were used for whole genome/exome sequencing and
mutational signatures were identified as described by Alexandrov et al.
As a result, whole-exome sequencing in breast cancer FFPE core biopsies
from clinical cohorts can be used to identify mutational signatures. The
pattern of these signatures, in particular the presence of BRCA-related
(Sig3) and APOBEC-related (Sig13), reflect the clinical behavior of
breast cancer and may be used to identify tumors with an increased
response rate to neoadjuvant chemotherapy.
About NantOmics
NantOmics, a member of the NantWorks
ecosystem of companies, delivers molecular analysis capabilities with
the intent of providing actionable intelligence and molecularly driven
decision support for cancer patients and their providers at the point of
care. NantOmics is the first molecular analysis company to pioneer an
integrated approach to unearthing the genomic and proteomic variances
that initiate and drive cancer, by analyzing both normal and tumor cells
from the same patient and following identified variances through from
DNA to RNA to protein to drug. NantOmics has a highly scalable
cloud-based infrastructure capable of storing and processing thousands
of genomes a day, computing genomic variances in near real-time, and
correlating proteomic pathway analysis with quantitative multi-plexed
protein expression analysis from the same micro-dissected tumor sample
used for genomic analysis. For more information please visit www.nantomics.com and
follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.
